{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T18:09:16Z","timestamp":1794766156713,"version":"4.9.1"},"reference-count":177,"publisher":"Elsevier","isbn-type":[{"value":"9780128233573","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/b978-0-12-823357-3.00009-4","type":"book-chapter","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T21:47:08Z","timestamp":1706824028000},"page":"67-86","source":"Crossref","is-referenced-by-count":9,"title":["Preventive treatment of migraine: Non-specific oral agents"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1526-4610.1992.hed3202101.x","article-title":"Fluoxetine prophylaxis of migraine","volume":"32","author":"Adly","year":"1992","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00207454.2011.626908","article-title":"A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis","volume":"122","author":"Afshari","year":"2012","journal-title":"Int J Neurosci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10194-009-0179-2","article-title":"A review of current European treatment guidelines for migraine","volume":"11","author":"Antonaci","year":"2010","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1474-4422(18)30434-4","article-title":"The most important advances in headache research in 2018","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0030","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.23768","article-title":"Comparing zonisamide with sodium valproate in the management of migraine headaches: double-blind randomized clinical trial of efficacy and safety","volume":"18","author":"Assarzadegan","year":"2016","journal-title":"Iran Red Crescent Med J"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ana.20778","article-title":"Suppression of cortical spreading depression in migraine prophylaxis","volume":"59","author":"Ayata","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1470320313503694","article-title":"Renin-angiotensin system in pain: existing in a double life?","volume":"15","author":"Bali","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2007.04.060","article-title":"Cardiovascular protection using beta-blockers: a critical review of the evidence","volume":"50","author":"Bangalore","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.wnf.0000192136.46145.44","article-title":"Efficacy of topiramate and valproate in chronic migraine","volume":"28","author":"Bartolini","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0055","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3923\/ijp.2010.670.675","article-title":"Assessment of the middle dose of topiramate in comparison with sodium valproate for migraine prophylaxis: a randomized double blind study","volume":"6","author":"Bavrasad","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1526-4610.1995.hed3508470.x","article-title":"ACE inhibitors for prophylaxis of migraine headaches","volume":"35","author":"Bender","year":"1995","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0065","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/0333102410384886","article-title":"Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT])","volume":"31","author":"Beran","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0070","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/head.13949","article-title":"Altered serum levels of renin-angiotensin system markers in migraine","volume":"60","author":"Bhering","year":"2020","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0075","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0080","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.nbd.2010.10.014","article-title":"Migraine preventive drugs differentially affect cortical spreading depression in rat","volume":"41","author":"Bogdanov","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0085","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/j.pain.0000000000001007","article-title":"Propranolol treatment prevents chronic central sensitization induced by repeated dural stimulation","volume":"158","author":"Boyer","year":"2017","journal-title":"Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: a randomized controlled trial","volume":"291","author":"Brandes","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1526-4610.1979.hed1907379.x","article-title":"Timolol in migraine prophylaxis","volume":"19","author":"Briggs","year":"1979","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12016","article-title":"Zonisamide: its pharmacology, efficacy and safety in clinical trials","volume":"194","author":"Brodie","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.46.2.465","article-title":"Valproic acid hepatic fatalities. III. U.S. experience since 1986","volume":"46","author":"Bryant","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0110","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/head.13615","article-title":"Lamotrigine in the prevention of migraine with aura: a narrative review","volume":"59","author":"Buch","year":"2019","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0333102414559733","article-title":"Association of statin use and risk for severe headache or migraine by serum vitamin D status: a cross-sectional population-based study","volume":"35","author":"Buettner","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.24534","article-title":"Simvastatin and vitamin D for migraine prevention: a randomized, controlled trial","volume":"78","author":"Buettner","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clineuro.2004.03.004","article-title":"Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study","volume":"107","author":"Bulut","year":"2004","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1254\/jphs.CR0050020","article-title":"Mechanisms of the antinociceptive action of gabapentin","volume":"100","author":"Cheng","year":"2006","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0135","first-page":"1005","article-title":"Comparison between topiramate and sodium valproate efficacy in the treatment of migraine","volume":"11","author":"Choudhary","year":"2017","journal-title":"Pakiston J Med Hlth Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","article-title":"Amitriptyline in the prophylactic treatment of migraine and chronic daily headache","volume":"51","author":"Couch","year":"2011","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0145","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/archneur.1979.00500470065013","article-title":"Amitriptyline in migraine prophylaxis","volume":"36","author":"Couch","year":"1979","journal-title":"Arch Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.26.2.121","article-title":"Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects","volume":"26","author":"Couch","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0155","first-page":"5734","article-title":"The efficacy and safety of valproate medications for migraine in adults: a meta-analysis","volume":"24","author":"Cui","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0160","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1526-4610.1999.3910716.x","article-title":"Fluoxetine for migraine prophylaxis: a double-blind trial","volume":"39","author":"D'amato","year":"1999","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0165","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.clinph.2007.06.060","article-title":"Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine","volume":"118","author":"Detommaso","year":"2007","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0170","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/TCRM.S3983","article-title":"Optimizing prophylactic treatment of migraine: subtypes and patient matching","volume":"4","author":"Dib","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0175","first-page":"943","article-title":"Topiramate in migraine prophylaxis\u2014results from a placebo-controlled trial with propranolol as an active control","volume":"251","author":"Diener","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0180","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S1474-4422(07)70272-7","article-title":"Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial","volume":"6","author":"Diener","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0185","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0190","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1468-2982.2008.01825.x","article-title":"Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial","volume":"29","author":"Diener","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0195","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/j.1528-1157.2000.tb06047.x","article-title":"Topiramate as am inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0200","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","article-title":"Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs","volume":"31","author":"Dodick","year":"2009","journal-title":"Clin Therapeutics"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0205","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1007\/s10072-007-0787-z","article-title":"Basilar-type migraine responsive to lamotrigine: three case reports","volume":"28","author":"D'onofrio","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11916-019-0823-8","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults","volume":"23","author":"Dorosch","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0215","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10072-013-1536-0","article-title":"A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine","volume":"35","author":"Engel","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0220","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine\u2014revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review","volume":"87","author":"Fava","year":"2018","journal-title":"Psychother Psychosom"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0230","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American geriatrics society 2019 updated AGS beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","author":"Fick","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0235","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1515\/jom-1984-841214","article-title":"Nadolol and placebo comparison study in the prophylactic treatment of migraine","volume":"84","author":"Freitag","year":"1984","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0240","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/WNL.58.11.1652","article-title":"A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis","volume":"58","author":"Freitag","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0245","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0091-3057(98)00116-6","article-title":"The role of angiotensin II and of its receptor subtypes in the acetic acid-induced abdominal constriction test","volume":"62","author":"Georgieva","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0250","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp.36.4.684","article-title":"Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial","volume":"36","author":"Gomersall","year":"1973","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0255","first-page":"347","article-title":"A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse","volume":"57","author":"Gracia-Naya","year":"2013","journal-title":"Rev Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0260","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1526-4610.2006.00599.x","article-title":"Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study)","volume":"47","author":"Gupta","year":"2007","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0265","first-page":"17","article-title":"Migraine headache prophylaxis","volume":"99","author":"Ha","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0270","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11910-010-0099-1","article-title":"Cortical spreading depression and migraine","volume":"10","author":"Haerter","year":"2010","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0275","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-3565(25)30125-4","article-title":"Induction of tyrosine hydroxylase elicited by beta adrenergic receptor agonists in normal and decentralized sympathetic ganglia: role of cyclic 3\u2032,5\u2032 - adenosine monophosphate","volume":"193","author":"Hanbauer","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0280","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1468-2982.1992.1202081.x","article-title":"Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo","volume":"12","author":"Hering","year":"1992","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0285","first-page":"783","article-title":"Comparison of pregabalin and sodium valproate in migraine prophylaxis: a randomized double-blinded study","volume":"17","author":"Hesami","year":"2018","journal-title":"Iranian J Pharmaceutical Res"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0290","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0031-6865(99)00030-8","article-title":"Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics","volume":"74","author":"Hieble","year":"2000","journal-title":"Pharm Acta Helv"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0295","series-title":"StatPearls [Internet]","article-title":"Angiotensin II receptor blockers (ARB)","author":"Hill","year":"2021"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0300","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/jcbfm.2010.92","article-title":"Gabapentin suppresses cortical spreading depression susceptibility","volume":"30","author":"Hoffman","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0305","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1526-4610.1991.hed3105333.x","article-title":"Propranolol in the management of recurrent migraine: a meta-analytic review","volume":"31","author":"Holroyd","year":"1991","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130733","article-title":"A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache","volume":"10","author":"Jackson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"Jackson","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0320","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/head.12480","article-title":"The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension","volume":"55","author":"Jion","year":"2015","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0325","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1574884712666170329094419","article-title":"Levetiracetam in compare to sodium valproate for prophylaxis in chronic migraine headache: a randomized double-blind clinical trial","volume":"12","author":"Kashipazha","year":"2017","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0330","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s10194-021-01234-6","article-title":"Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial","volume":"22","author":"Khani","year":"2021","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0335","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/AJP.0000000000000739","article-title":"Individualization of migraine prevention: a randomized controlled trial of psychophysical-based prediction of duloxetine efficacy","volume":"35","author":"Kisler","year":"2019","journal-title":"Clin J Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0340","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1468-2982.1997.1702103.x","article-title":"Divalproex sodium in migraine prophylaxis: a dose-controlled study","volume":"17","author":"Klapper","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0345","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1526-4610.2002.02125.x","article-title":"Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study","volume":"42","author":"Krymchantowski","year":"2002","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0350","series-title":"StatPearls [internet]","article-title":"Migraine prophylaxis","author":"Kumar","year":"2020"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0355","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/ane.12626","article-title":"Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial","volume":"135","author":"Lai","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0360","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/jnnp.2005.063750","article-title":"Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura","volume":"76","author":"Lampl","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0365","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s10792-017-0740-y","article-title":"Bilateral acute angle closure glaucoma and myopic shift by topiramate-induced ciliochoroidal effusion: case report and literature review","volume":"38","author":"Lan","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0370","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0140-6736(64)91866-5","article-title":"Treatment of chronic tension headache","volume":"1","author":"Lance","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0375","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1526-4610.1985.hed2502107.x","article-title":"Clomipramine and metoprolol in migraine prophylaxis\u2014a double-blind crossover study","volume":"25","author":"Langohr","year":"1985","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0380","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1161\/CIRCULATIONAHA.104.529628","article-title":"Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants","volume":"112","author":"Law","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0385","doi-asserted-by":"crossref","first-page":"s43","DOI":"10.1007\/s101940170008","article-title":"The serotonergic system in migraine","volume":"2","author":"Leone","year":"2001","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0390","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.12659\/MSM.900185","article-title":"Valproate attenuates nitroglycerin-induced trigeminovascular activation by preserving mitochondrial function in a rat model of migraine","volume":"22","author":"Li","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0395","first-page":"Cd003225","article-title":"Propranolol for migraine prophylaxis","volume":"2","author":"Linde","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0400","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/head.13375","article-title":"Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018","volume":"58","author":"Loder","year":"2018","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0405","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","article-title":"The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines","volume":"52","author":"Loder","year":"2012","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0410","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0415","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1526-4637.2011.01295.x","article-title":"A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis","volume":"13","author":"Luo","year":"2012","journal-title":"Pain Med"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0420","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clineuro.2010.02.004","article-title":"Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine","volume":"112","author":"Magalhaes","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0425","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1526-4610.1981.hed2103105.x","article-title":"Prophylaxis of migraine and mixed headache. A randomized controlled study","volume":"21","author":"Mathew","year":"1981","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0430","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/archneur.1995.00540270077022","article-title":"Migraine prophylaxis with divalproex","volume":"52","author":"Mathew","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0435","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1526-4610.2001.111006119.x","article-title":"Efficacy of gabapentin in migraine prophylaxis","volume":"41","author":"Mathew","year":"2001","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0440","series-title":"StatPearls [Internet]","article-title":"Calcium channel blockers","author":"Mckeever","year":"2020"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0445","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00415-020-09989-9","article-title":"Candesartan in migraine prevention: results from a retrospective real-world study","volume":"267","author":"Messina","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0450","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNF.0b013e318225140c","article-title":"Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial","volume":"34","author":"Mohammadianinejad","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002919.pub2","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches","author":"Moja","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0460","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3390\/ijms18112483","article-title":"Analgesic mechanisms of antidepressants for neuropathic pain","volume":"18","author":"Obata","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0465","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2217\/cer-2018-0074","article-title":"Real-world assessment of treatment with extended-release topiramate (Trokendi XR\u00ae) and comparison with previous immediate-release topiramate treatment","volume":"7","author":"O'Neal","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0470","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamaneurol.2017.5144","article-title":"Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome","volume":"75","author":"Orlova","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0475","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000116104","article-title":"Add-on therapy in epilepsy with calcium entry blockers","volume":"25","author":"Overweg","year":"1986","journal-title":"Eur Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0480","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","article-title":"The efficacy and safety of venlafaxine in the prophylaxis of migraine","volume":"45","author":"Ozyalcin","year":"2005","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0485","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/0333102413520086","article-title":"Familial hemiplegic migraine treated by sodium valproate and lamotrigine","volume":"34","author":"Pelzer","year":"2014","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0490","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1468-2982.2009.01946.x","article-title":"Topiramate-induced depression in cases using topiramate for migraine prophylaxis","volume":"30","author":"Phabphal","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0495","first-page":"S1","article-title":"Canadian headache society prophylactic guidelines development group. Canadian headache society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0500","first-page":"S1","article-title":"Canadian headache society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0505","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1097\/WNR.0000000000000269","article-title":"Upregulating serotonin transporter expression and downregulating monoamine oxidase-A and indoleamine 2, 3-dioxygenase expression involved in the antidepressant effect of sodium valproate in a rat model","volume":"25","author":"Qiu","year":"2014","journal-title":"Neuroreport"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0510","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0002-9149(66)90056-7","article-title":"The prophylactic value of propranolol in angina pectoris","volume":"18","author":"Rabkin","year":"1966","journal-title":"Am J Cardiol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0515","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1526-4610.2006.00506.x","article-title":"Long-term migraine prevention with topiramate: open-label extension of pivotal trials","volume":"46","author":"Rapoport","year":"2006","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11940-019-0559-0","article-title":"Other preventive anti-migraine treatments: ACE inhibitors, ARBs, Calcium Channel blockers, serotonin antagonists, and NMDA receptor antagonists","volume":"21","author":"Rau","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0525","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/14737175.2014.946408","article-title":"The renin-angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis","volume":"14","author":"Ripa","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0530","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/head.12273","article-title":"Preventive pharmacotherapy in migraine","volume":"54","author":"Rizzoli","year":"2014","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0535","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1526-4610.2011.01985.x","article-title":"Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms","volume":"51","author":"Rizzoli","year":"2011","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0540","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0896-6273(00)80144-0","article-title":"Characterization of multiple phosphorylation sites on the AMP receptor GluR1 subunit","volume":"16","author":"Roche","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0545","first-page":"75","article-title":"Aetiology of migraine and prevention with carbamazepine (tegretol): results of a double-blind, cross-over study","volume":"44","author":"Rompel","year":"1970","journal-title":"S Afr Med J"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0550","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FOWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0555","first-page":"89","article-title":"Nadolol and placebo comparison study in the prophylactic treatment of migraine","volume":"24","author":"Ryan","year":"1982","journal-title":"Panminerva Med"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0560","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/0002-8703(84)90600-8","article-title":"Comparative study of nadolol and propranolol in prophylactic treatment of migraine","volume":"108","author":"Ryan","year":"1984","journal-title":"Am Heart J"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0565","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10571-005-4011-5","article-title":"Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities","volume":"25","author":"Saavedra","year":"2005","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0570","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1528-1157.1997.tb01120.x","article-title":"Topiramate monotherapy for partial onset seizures","volume":"38","author":"Sachdeo","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0972-2327.144290","article-title":"Comparison of levetiracetam and sodium valproate in migraine prophylaxis: a randomized placebo-controlled study","volume":"18","author":"Sadeghian","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0580","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/S0024-3205(00)00841-9","article-title":"Pain threshold, learning and formation of brain edema in mice lacking the angiotensin II type 2 receptor","volume":"67","author":"Sakagawa","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0585","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41598-021-83508-2","article-title":"Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study","volume":"11","author":"S\u00e1nchez-Rodr\u00edguez","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0590","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1526-4610.1994.hed3409497.x","article-title":"Double-blind trial of fluoxetine: chronic daily headache and migraine","volume":"34","author":"Saper","year":"1994","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0595","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/0333102409359709","article-title":"Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate","volume":"30","author":"Schoenen","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0600","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1468-1331.2007.01764.x","article-title":"Efficacy of lisinopril in migraine prophylaxis\u2014an open label study","volume":"14","author":"Schuh-Hofer","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0605","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10072-015-2458-9","article-title":"Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients","volume":"37","author":"Sedighi","year":"2016","journal-title":"Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0610","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s11606-013-2433-1","article-title":"Preventive pharmacologic treatments for episodic migraine in adults","volume":"28","author":"Shamliyan","year":"2013","journal-title":"J Gen Intern Med"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0615","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0620","first-page":"1","article-title":"The comparative study of sodium valproate and topiramate as prophylactic therapy for migraine in Imam hospitals of Tabriz and Urmia, Northwestern Iran","volume":"6","author":"Sharifi","year":"2012","journal-title":"J Appl Biol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0625","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1468-2982.1981.0104229.x","article-title":"Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache)","volume":"1","author":"Sicuteri","year":"1981","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0630","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10799899509045224","article-title":"Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorylation","volume":"15","author":"Sigel","year":"1995","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0635","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.55.6.754","article-title":"Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Silberstein","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0640","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1526-4610.2002.02020.x","article-title":"Control of topiramate-induced paresthesias with supplemental potassium","volume":"42","author":"Silberstein","year":"2002","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0645","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study","volume":"61","author":"Silberstein","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0650","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1526-4610.2005.4501005.x","article-title":"Topiramate in migraine prevention","volume":"45","author":"Silberstein","year":"2005","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0655","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tips.2006.06.003","article-title":"Preventive treatment of migraine","volume":"27","author":"Silberstein","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0660","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0665","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/head.12997","article-title":"Topiramate in migraine prevention: a 2016 perspective","volume":"57","author":"Silberstein","year":"2017","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0670","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1468-2982.2002.00386.x","article-title":"Migraine: preventive treatment","volume":"22","author":"Silberstein","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0675","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.wnl.0000297551.27191.70","article-title":"Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study","volume":"70","author":"Silberstein","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0680","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0685","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","article-title":"Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0690","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0333102412466968","article-title":"Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis","volume":"33","author":"Silberstein","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0695","series-title":"The Prescriber's guide","article-title":"Essential Neuropharmacology","author":"Silberstein","year":"2015"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0700","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1745-6215-11-71","article-title":"P3MC: a double blind parallel group randomised placebo controlled trial of propranolol and Pizotifen in preventing migraine in children","volume":"11","author":"Silcocks","year":"2010","journal-title":"Trials"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0705","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1526-4610.1985.hed2507368.x","article-title":"Comparative efficacy of calcium antagonist drugs in the prophylaxis of migraine","volume":"25","author":"Solomon","year":"1985","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0710","first-page":"72","article-title":"Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Sonbolestan","year":"2013","journal-title":"Int J Prev Med"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0715","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003495-197203030-00002","article-title":"Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches","volume":"3","author":"Speight","year":"1972","journal-title":"Drugs"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0720","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","article-title":"Current prophylactic medications for migraine and their potential mechanisms of action","volume":"15","author":"Sprenger","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0725","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1468-2982.1997.1702109.x","article-title":"Lamotrigine versus placebo in the prophylaxis of migraine with and without aura","volume":"17","author":"Steiner","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0730","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1468-2982.1998.1805283.x","article-title":"S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study","volume":"18","author":"Steiner","year":"1998","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0735","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","article-title":"Migraine is first cause of disability in under 50s: will health politicians now take notice?","volume":"19","author":"Steiner","year":"2018","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0740","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","article-title":"Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache","volume":"20","author":"Steiner","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0745","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/jama.1984.03350180030025","article-title":"Migraine prevention with timolol. A double-blind crossover study","volume":"252","author":"Stellar","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0750","first-page":"A238","article-title":"Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine","volume":"60","author":"Storer","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0755","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1046\/j.1526-4610.2001.01190.x","article-title":"Topiramate in migraine prevention: a double-blind, placebo-controlled study","volume":"41","author":"Storey","year":"2001","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0760","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study","volume":"34","author":"Stovner","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0765","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/j.pain.0000000000001456","article-title":"Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis","volume":"160","author":"Stubberud","year":"2019","journal-title":"Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0770","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1526-4610.1987.hed2708421.x","article-title":"Comparative efficacy of nadolol and propranolol in the management of migraine","volume":"27","author":"Sudilovsky","year":"1987","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0775","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/WNF.0b013e3181a8c84f","article-title":"Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders","volume":"32","author":"Tarlaci","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0780","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0733-8619(05)70301-7","article-title":"Prophylactic pharmacotherapy of migraine. Some practical guidelines","volume":"15","author":"Tfelt-Hansen","year":"1997","journal-title":"Neurol Clin"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.1984.tb07772.x","article-title":"Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial","volume":"69","author":"Tfelt-Hansen","year":"1984","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0790","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14737175.2020.1787834","article-title":"Cinnarizine as an alternative recommendation for migraine prophylaxis: a narrative review","volume":"20","author":"Togha","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0795","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.jacc.2014.01.054","article-title":"Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins","volume":"63","author":"Tousoulis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0800","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11916-014-0417-4","article-title":"Role of angiotensin modulation in primary headaches","volume":"18","author":"Tronvik","year":"2014","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0805","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.289.1.65","article-title":"Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial","volume":"289","author":"Tronvik","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0810","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.hjh.0000220419.86149.11","article-title":"Involvement of the renin-angiotensin system in migraine","volume":"24","author":"Tronvik","year":"2006","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0815","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-019-02790-2","article-title":"Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis","volume":"76","author":"Tsaousi","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0820","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s10194-018-0898-3","article-title":"Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation","volume":"19","author":"Vatzaki","year":"2018","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0825","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WNF.0000000000000005","article-title":"Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India","volume":"36","author":"Verma","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0830","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Vos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0835","first-page":"21","article-title":"Prevention of migraine using flunarizine (results of a pilot study using Amalium)","volume":"137","author":"Wessely","year":"1987","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0840","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1526-4610.2005.00262.x","article-title":"Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial","volume":"45","author":"Winner","year":"2005","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0845","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2008.01.023","article-title":"Labetalol facilitates GABAergic transmission to rat periaqueductal gray neurons via antagonizing beta1-adrenergic receptors\u2014a possible mechanism underlying labetalol-induced analgesia","volume":"1198","author":"Xiao","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0850","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/WNF.0000000000000425","article-title":"The efficacy of memantine for the treatment of migraine: a meta-analysis of randomized controlled studies","volume":"44","author":"Xu","year":"2021","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0855","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.pain.2012.02.021","article-title":"Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy","volume":"153","author":"Yarnitsky","year":"2012","journal-title":"Pain"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0860","first-page":"2649","article-title":"Flunarizine inhibits sensory neuron excitability by blocking voltage-gated Na+ and Ca2+ currents in trigeminal ganglion neurons","volume":"124","author":"Ye","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0865","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neulet.2010.10.064","article-title":"Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: A possible locus of action in the prevention of migraine","volume":"487","author":"Ye","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0870","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jfma.2020.08.020","article-title":"Efficacy of levetiracetam for migraine prophylaxis: a systematic review and meta-analysis","volume":"12","author":"Yen","year":"2021","journal-title":"J Formosan Med Assoc"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0875","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/head.12205","article-title":"Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study","volume":"53","author":"Young","year":"2013","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0880","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","article-title":"Modulation of high voltage-activated calcium channels in dentate granule cells by topiramate","volume":"41","author":"Zhang","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0885","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archneur.1987.00520170016015","article-title":"Migraine prophylaxis. A comparison of propranolol and amitriptyline","volume":"44","author":"Ziegler","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00009-4_bb0890","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3940(97)00543-0","article-title":"Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells","volume":"231","author":"Zona","year":"1997","journal-title":"Neurosci Lett"}],"container-title":["Handbook of Clinical Neurology","Migraine Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128233573000094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128233573000094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T13:19:26Z","timestamp":1753967966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128233573000094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780128233573"],"references-count":177,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-823357-3.00009-4","relation":{},"ISSN":["0072-9752"],"issn-type":[{"value":"0072-9752","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}